Non-muscle Invasive Bladder Cancer Therapeutics and Forecast Market

List of Tables
Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-muscle Invasive Bladder Cancer Therapeutics in Global Market
Table 5. Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2024-2030
Table 30. F. Hoffmann-La Roche Ltd. Company Summary
Table 31. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 32. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. F. Hoffmann-La Roche Ltd. Key News & Latest Developments
Table 34. Bristol-Myers Squibb Company Company Summary
Table 35. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 36. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Bristol-Myers Squibb Company Key News & Latest Developments
Table 38. AstraZeneca Company Summary
Table 39. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 40. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. AstraZeneca Key News & Latest Developments
Table 42. Pfizer Inc. Company Summary
Table 43. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 44. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Inc. Key News & Latest Developments
Table 46. GlaxoSmithKline plc. Company Summary
Table 47. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 48. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. GlaxoSmithKline plc. Key News & Latest Developments
Table 50. Sanofi S.A. Company Summary
Table 51. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 52. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Sanofi S.A. Key News & Latest Developments
Table 54. Novartis AG Company Summary
Table 55. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 56. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. Novartis AG Key News & Latest Developments
Table 58. Eli Lilly and Company Company Summary
Table 59. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 60. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 61. Eli Lilly and Company Key News & Latest Developments
Table 62. Merck & Co. Company Summary
Table 63. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 64. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 65. Merck & Co. Key News & Latest Developments
Table 66. Viventia Bio Inc. Company Summary
Table 67. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 68. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 69. Viventia Bio Inc. Key News & Latest Developments
Table 70. Celgene Corporation Company Summary
Table 71. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 72. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 73. Celgene Corporation Key News & Latest Developments
Table 74. Spectrum Pharmaceuticals, Inc. Company Summary
Table 75. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 76. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 77. Spectrum Pharmaceuticals, Inc. Key News & Latest Developments
Table 78. Herantis Pharma Plc. Company Summary
Table 79. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 80. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 81. Herantis Pharma Plc. Key News & Latest Developments
Table 82. Taris Biomedical LLC Company Summary
Table 83. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 84. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 85. Taris Biomedical LLC Key News & Latest Developments
Table 86. Prometic Life Sciences Inc. Company Summary
Table 87. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 88. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 89. Prometic Life Sciences Inc. Key News & Latest Developments
Table 90. Telormediz S.A. Company Summary
Table 91. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 92. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 93. Telormediz S.A. Key News & Latest Developments
Table 94. Heat Biologics Company Summary
Table 95. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 96. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 97. Heat Biologics Key News & Latest Developments
Table 98. Altor BioScience Company Summary
Table 99. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 100. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 101. Altor BioScience Key News & Latest Developments
Table 102. Ferring B.V. Company Summary
Table 103. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 104. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 105. Ferring B.V. Key News & Latest Developments
Table 106. Cold Genesys Inc. Company Summary
Table 107. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 108. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 109. Cold Genesys Inc. Key News & Latest Developments
List of Figures
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type in 2022
Figure 2. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application in 2022
Figure 3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2022
Figure 8. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 9. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 10. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 12. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 14. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 15. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 16. US Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 20. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 21. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 28. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 32. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 34. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2018-2030
Figure 37. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2018-2030
Figure 41. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)